Merck + Co., Inc.

Abbott Laboratories Corporation

Merck Sharp + Dohme Corp.

Merck Frosst Canada, Inc.

Merck Canada Inc.

John Y Chung

Dalian Zhao

David L Hughes

David S Garvey

Nobuyoshi Yasuda

Michel M Chartrain

Christopher Roberge

Johnnie L Leazer, Jr

Jeffrey C Moore

Yves Girard

Pierre A Hamel

Gregory Hughes

Michael D Tufano

David J Mathre

Mark W Holladay

Kenneth M Wells

Paul D May

Alex M Nadzan

Chunhua Yang

Kevin Matthew Maloney

James M McNamara

Robert A Reamer

Christophe Mellon

Paul O'Shea

Mark S Jensen

Kazumi Shiosaki

Louis-Charles Campeau

Youe-Kong Shue

Danny Gauvreau

Melina Girardin-Rondeau

Stephane Ouellet

Mark S Brodie

The present invention is directed to processes for preparing a pyridyl piperidine compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

Process for the preparation of an orexin receptor antagonist

Crystalline 2-hydroxymethyl carbapenem intermediate compounds and process for synthesis thereof

A process of synthesizing a compound of formula I is described: ##STR1## wherein P and P' independently represent H or a protecting group, R.sub.1 represents H or C.sub.1-4 alkyl, and Hal represents a halogen characterized by reacting a compound of formula 2: ##STR2## with R.sub.2 OH, wherein R.sub.2 is C.sub.1-4 alkyl, C.sub.6-10 aryl or C.sub.5-10 heteroaryl in the presence of an acid catalyst or carbodiimide reagent to produce a compound of formula 3: ##STR3## and reacting a compound of formula 3 in the presence of a base and a haloalkylating agent to produce a compound of formula 1.

Process for synthesizing carbapenem intermediates

Asymmetric bioreduction of a ketone substrate with yeast produces the corresponding (R)-alcohol of structure: ##STR1## a key intermediate in the synthesis of a .beta..sub.3 -agonist of structure ##STR2##

N-(R)-(2-hydroxy-2-pyridine-3-yl-ethyl)-2-(4-nitro-phenyl)-acetamide

Compound 9 is prepared by a 9-step ##STR1## process in an overall yield of about 35% from 3-acetylpyridine. Compound 10 is prepared by a seven-step ##STR2## process in an overall yield of about 30% from 3-acetyl pyridine. These compounds are key intermediates in the synthesis of Compound 11, an important .beta.-3 agonist useful in the treatment of obesity and diabetes. ##STR3##

Process for

Pyridyl ethylation of lactam derivatives

Pyridyl ethylation of lactams

Peptide analog type-B CCK receptor ligands or pharmaceutically-acceptable salts thereof, which are useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and for the treatment of shock, respiratory and cardiocirculatory insufficiencies.

Peptide analog type-B CCK receptor ligands

Compounds having the formula I: ##STR1## are inhibitors of the 5-lipoxygenase enzyme and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, psoriasis, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.

Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene

The invention is a highly efficient synthesis for making compounds of the formula: ##STR1## wherein: R.sup.1 is a six membered saturated or unsaturated heterocyclic ring containing one or two heteroatoms wherein the heteroatoms are N; or NR.sup.6, wherein R.sup.6 is H or C.sub.1-10 alkyl;

Process for preparing fibrinogen receptor antagonists

Aza-spirocyclic compounds of formula (I) ##STR1## which enhance cortical cholinergic neurotransmission.

Aza-spirocyclic compounds that enhance cholinergic neurotransmission

The invention is a highly efficient synthesis for making compounds of the formula: ##STR1## wherein: R.sup.1 is a six member saturated or unsaturated heterocyclic ring containing one or two heterocyclic atoms wherein the heteroatoms are N; or NR.sup.6, wherein R.sup.6 is H or C.sub.1-10 alkyl;

Growing community of inventors

Edison, NJ, United States of America

John Y Chung